Login
Cara Therapeutics NASDAQ: CARA
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed
| Name | Cara Therapeutics |
| Ticker | CARA |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Price | 19.65 |
| 52W Low/High | 9.12 / 20.26 |
| Market cap | 921 M |
| 1Y Total Return |
22.43%
Above Average |
| 1Y Volatility |
60.30%
Average Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed
Details
| Ticker | CARA |
| Name | Cara Therapeutics |
| ISIN | US1407551092 |
| CUSIP | 140755109 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Cannabinoid Therapeutics |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/25/21
| Close Price | 19.65 |
| 52W Low/High | 9.12 / 20.26 |
| Market cap | 921 M |
| 1Y Total Return |
22.43%
Above Average |
| 1Y Volatility |
60.30%
Average Risk |
| Beta | 1.78 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -360.3% |
| Cash from Op. / Cur. Liabilities | -7.15 |
| Diluted Earnings / Share | -2.12 |
| ROE | - |
| ROIC | -84.3% |
| Price / Revenue | 33.5 |
| Price / Book | 7.2 |
| Price / CF | -7.8 |
| Current Ratio | 8.0 |
| Cur.Liabilities / Tot.Liabilities | 0.9 |
| Financial Leverage | 0.03 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
28
|
21
|
8
|
1
|
0
|
5
|
|
| Gross Profit |
28
|
21
|
8
|
1
|
0
|
5
|
|
| R&D |
111
|
107
|
64
|
57
|
37
|
17
|
|
| EBITDA |
-99
|
-99
|
-67
|
-66
|
-44
|
-19
|
|
| Operating Income |
-103
|
-104
|
-70
|
-67
|
-46
|
-20
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
47
|
45
|
38
|
33
|
27
|
26
|
|
| EPS exc. Extra |
-2.12
|
-2.40
|
-1.97
|
-2.29
|
-1.65
|
-0.83
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
147
|
264
|
213
|
108
|
80
|
118
|
|
| Cash, Eq & Invt ShortTerm |
121
|
193
|
207
|
104
|
73
|
112
|
|
| Total Current Assets |
133
|
203
|
211
|
106
|
77
|
116
|
|
| Total Non-Current Assets |
14
|
60
|
1
|
2
|
3
|
2
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
19
|
52
|
63
|
9
|
8
|
4
|
|
| Total Current Liabilities |
17
|
48
|
43
|
7
|
7
|
3
|
|
| Long Term Debt |
3
|
4
|
20
|
2
|
2
|
1
|
|
| Shareholder equity |
128
|
212
|
150
|
99
|
72
|
114
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-119
|
-102
|
-9
|
-57
|
-38
|
-23
|
|
| Depreciation |
1
|
1
|
0
|
0
|
2
|
1
|
|
| Cash from Investing |
159
|
-103
|
-17
|
-24
|
-67
|
0
|
|
| Capex |
0
|
0
|
0
|
0
|
1
|
0
|
|
| Cash from Financing |
1
|
143
|
110
|
88
|
0
|
76
|
|
| Stock Issued |
1
|
143
|
110
|
88
|
0
|
76
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-18
|
-145
|
-51
|
-90
|
-103
|
-24
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
8.0
|
4.2
|
4.9
|
14.6
|
11.3
|
34.3
|
|
| Financial Leverage D/E |
0.03
|
0.02
|
0.00
|
0.00
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-84.3%
|
-77.7%
|
-84.7%
|
-85.4%
|
-128.1%
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available